Gastroenterology
Glecirasib, Alone and with Cetuximab, Shows Activity in KRASG12C-Mutant Colorectal Cancer — Combination Nearly Doubles Response Rate
Phase 1/2 data show oral glecirasib has single-agent activity (ORR 23%) in KRASG12C colorectal cancer; adding cetuximab raises ORR to 50% with manageable toxicity, supporting further randomized testing and earlier-line combination strategie
